CADL · Candel Therapeutics, Inc.
$12.35
-1.15 (-8.52%)
At close · Aug 20
Market Cap
$922.05M
Shares
76.52M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-13 | 2026-06-30 | |
| 8-K | 2026-08-13 | — | |
| Investor Event Transcript | 2026-08-12 | 2026-09-30 | |
| 8-K | 2026-06-24 | 2026-06-23 | |
| 8-K | 2026-06-16 | 2026-06-12 | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| Investor Event Transcript | 2026-05-15 | 2026-06-30 | |
| 8-K | 2026-05-15 | — | |
| 8-K | 2026-05-14 | — | |
| 10-Q | 2026-05-14 | 2026-03-31 | |
| DEF 14A | 2026-04-29 | 2026-06-23 | |
| 10-K | 2026-03-12 | 2025-12-31 | |
| 8-K | 2026-03-12 | — | |
| 8-K | 2026-02-23 | 2026-02-19 | |
| 8-K | 2026-02-19 | — | |
| 8-K | 2025-12-05 | — | |
| 8-K | 2025-11-13 | — | |
| 10-Q | 2025-11-13 | 2025-09-30 | |
| 8-K | 2025-10-14 | — | |
| 8-K | 2025-08-21 | 2025-08-18 | |
| 8-K | 2025-08-14 | — | |
| 10-Q | 2025-08-14 | 2025-06-30 | |
| 8-K | 2025-06-24 | 2025-06-23 | |
| 8-K | 2025-06-23 | 2025-06-20 | |
| 8-K | 2025-06-18 | 2025-06-17 | |
| 8-K | 2025-06-06 | 2025-06-04 | |
| 8-K | 2025-05-28 | — | |
| 8-K | 2025-05-22 | — | |
| 10-Q | 2025-05-13 | 2025-03-31 | |
| 8-K | 2025-05-13 | — | |
| DEF 14A | 2025-04-29 | 2025-06-17 | |
| 8-K | 2025-04-23 | — | |
| 8-K | 2025-03-27 | 2025-03-26 | |
| 8-K | 2025-03-13 | — | |
| 10-K | 2025-03-13 | 2024-12-31 | |
| 8-K | 2025-02-25 | — | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2024-12-13 | 2024-12-12 | |
| 8-K | 2024-12-11 | — | |
| 10-Q | 2024-11-14 | 2024-09-30 | |
| 8-K | 2024-11-14 | — | |
| 8-K | 2024-10-28 | — | |
| 8-K | 2024-08-13 | — | |
| 10-Q | 2024-08-13 | 2024-06-30 | |
| 8-K | 2024-06-28 | 2024-06-26 | |
| 8-K | 2024-05-30 | 2024-05-29 | |
| DEF 14A | 2024-05-30 | 2024-06-26 | |
| 8-K | 2024-05-23 | — | |
| 8-K | 2024-05-14 | — | |
| 10-Q | 2024-05-14 | 2024-03-31 |
Showing 1–50 of 114 filings
Key facts
CIK
1841387
CUSIP
137404109
13F (30d)
133 filings
132 filers
Visit website
Investor relations